2020.11.09
Initial monotherapy results demonstrate differentiated safety and PK profile and efficacy signal of lemzoparlimab for the treatment of relapsed/refractory malignancy.
2020.10.28
I-Mab today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follows.
2020.10.27
Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope.
2020.10.15
Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy.
2020.09.30
I-Mab today announced that the China Center for Drug Evaluation has approved the pivotal trial application for eftansomatropin as a weekly treatment for growth hormone deficiency in pediatric patients.
2020.09.21
I-Mab today announced that the Center for Drug Evaluation of the China National Medical Products Administration has cleared the Investigational New Drug application for lemzoparlimab to initiate a phase 1 clinical trial in patients with relapsed or refractory advanced lymphoma as part of an ongoing ...
2020.09.17
MorphoSys and I-Mab today jointly announced that the U.S. FDA has cleared the IND application for MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors. The phase 1 clinical trial, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210...
2020.09.08
I-Mab today announced its participation in the following conferences in September, including Cantor Fitzgerald Virtual Global Healthcare Conference 2020, Jefferies Virtual Asia Forum, ICBCI Virtual ADR New Economy Conference, 2020 Huatai USA Autumn Virtual China Conference, and Morgan Stanley Virtua...
2020.09.04
I-Mab today announced that it has entered into definitive subscription agreements with a consortium of institutional investors to raise approximately US$418 million through a private placement.
2020.09.04
AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two p...